Fig. 10From: Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid betaMetabolic activity of neuro2a cells after treatment with Aβ and recombinant antibodies measured by MTT assay. a Cells were incubated for 24 h with Aβ1-42 aggregates alone (500 nM) or in combination with 150 nM of the antibodies. PBS was used as a negative control and H2O2 as a positive control in all the experiments. Results are presented as MTT signal relative to PBS as 100%. Results are obtained from two repetitive experiments, where five to six replicates were used in each experiment. Data are presented as mean ± SD. One-way ANOVA was used followed by Dunnett’s post hoc test. A P-value of less than 0.05 refers to the presence of statistically significant differences. b Schematic representation of the ability of RmAb158, Tetra-RmAb158 and Hexa-RmAb158 to reduce cell metabolism impairments induced by a mixture of AβBack to article page